drugset
drugset / Trial / NCT05361005

Tolerability and Safety of BDB-001 Injection in Healthy Subjects

NCT05361005 ↗

Phase 1 Completed 33 enrolled Staidson (Beijing) Biopharmaceuticals Co., Ltd Beijing Defengrei Biotechnology Co.,Ltd · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A clinical study to evaluate the tolerability, PK and PD characteristics of BDB-001 Injection in healthy subjects.

Timeline

Start
2020-03-12
Primary completion
2020-05-08
Completion
2020-05-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Resiquimod Small molecule 2 mg/kg Intravenous
Subject Resiquimod Small molecule 4 mg/kg Intravenous
Subject Resiquimod Small molecule 8 mg/kg Intravenous

Indications

No indication recorded.